（Beijing, Shanghai, Boston）, November 13, 2025 – Jacobio Pharma (1167.HK) today announced the establishment of a Co-Chief Executive Officer (Co-CEO) structure. Dr. Yinxiang Wang, Founder, Chairman and CEO, will serve alongside Dr. Andrea Wang-Gillam, M.D., Ph.D., currently Chief Medical Officer of the Company, as Co-CEOs.   

Under this new framework, Dr. Yinxiang Wang will continue to lead Jacobio’s overall strategic planning, major corporate decisions and global R&D management, while Dr. Andrea Wang-Gillam will oversee international business development, global clinical operations and partnerships.  

The Co-CEO system marks a significant milestone in Jacobio’s globalization journey. By integrating the two leaders’ complementary expertise and regional strengths, Jacobio will further enhance its global execution capabilities and innovation efficiency through a “Global Strategy + Regional Execution” dual-track model.  

Dr. Yinxiang Wang, Founder, Chairman and Co-CEO of Jacobio Pharmaceuticals, said:“Jacobio is entering an exciting phase of global expansion. The Co-CEO structure is a natural step in strengthening our international management capabilities. Andrea’s profound experience in global clinical development and cross-cultural team leadership will further enhance our ability to execute and collaborate globally. Together, we aim to build Jacobio into a truly global innovative biotech company.”  

Dr. Andrea Wang-Gillam, M.D., Ph.D., Co-CEO of Jacobio Pharmaceuticals, added:“It is a great honor to serve as Co-CEO alongside Dr. Xinxiang Wang. I am deeply inspired by Jacobio’s scientific spirit and commitment to innovation. With my medical background and global clinical experience, I look forward to accelerating the development and global reach of our pipeline to bring more therapeutic options to patients worldwide.”  

Dr. Wang-Gillam is an internationally recognized oncologist with over 20 years of experience in clinical research and development. Prior to joining Jacobio in 2020, she was an Associate Professor at Washington University in St. Louis, where she led multiple global clinical studies in gastrointestinal oncology. At Jacobio, she has played a pivotal role in the China NDA of gelacirasib and advancing key oncology programs through global clinical development and regulatory approvals in China and beyond.  

About Jacobio Pharma  

Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company’s core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio’s  R&D centers are located in Beijing, Shanghai (China), and Boston (USA). Clinical trials are conducted at over 180 sites in China, more than 30 sites in the USA, and over 10 sites across several European countries.   

For more information, please visit: http://www.jacobiopharma.com  

About Jacobio